Sant Cugat del Vallès, Spain

Lucas Moreno Martín-retortillo

This inventor holds 1 USPTO granted patent. Top assignee: Bcn Peptides S.a.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lucas Moreno Martín-retortillo. Retrieved from https://idiyas.com/inventor/lucas-moreno-martín-retortillo

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 12.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Lucas Moreno Martín-retortillo

Introduction

Lucas Moreno Martín-retortillo is a notable inventor based in Sant Cugat del Vallès, Spain. He has made significant contributions to the field of cancer treatment through his innovative research and development of peptides.

Latest Patents

Lucas holds a patent titled "Peptides for the Treatment of Cancer and/or Metastasis." This patent represents a crucial advancement in the fight against cancer, showcasing his dedication to improving medical therapies.

Career Highlights

Lucas is associated with Bcn Peptides S.A., where he applies his expertise in peptide research. His work has the potential to impact the lives of many individuals affected by cancer.

Collaborations

Lucas collaborates with talented professionals such as Carla Molist Muñoz and Jimena Fernández Carneado. Their combined efforts contribute to the innovative environment at Bcn Peptides S.A.

Conclusion

Lucas Moreno Martín-retortillo exemplifies the spirit of innovation in the medical field, particularly in cancer treatment. His work and collaborations continue to pave the way for future advancements in healthcare.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…